X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Elder Pharma with Sun Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs SUN PHARMA - Comparison Results

SUN PHARMA 
   Change

Sun Pharma holds 3.7% share of the domestic pharma market (as per the latest ORG IMS MAT data) and has a strong presence in the lifestyle therapeutic segments. The company started focusing on the exports market in FY02, when it increased its stake to... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA SUN PHARMA ELDER PHARMA/
SUN PHARMA
 
P/E (TTM) x -0.2 25.6 - View Chart
P/BV x 0.1 3.7 2.7% View Chart
Dividend Yield % 0.0 0.6 -  

Financials

 ELDER PHARMA   SUN PHARMA
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
SUN PHARMA
Mar-17
ELDER PHARMA/
SUN PHARMA
5-Yr Chart
Click to enlarge
High Rs380842 45.1%   
Low Rs188572 32.8%   
Sales per share (Unadj.) Rs491.2131.6 373.2%  
Earnings per share (Unadj.) Rs-3.232.7 -9.7%  
Cash flow per share (Unadj.) Rs14.438.0 37.9%  
Dividends per share (Unadj.) Rs03.50 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs376.5152.7 246.5%  
Shares outstanding (eoy) m20.542,399.26 0.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.65.4 10.8%   
Avg P/E ratio x-89.321.6 -412.7%  
P/CF ratio (eoy) x19.718.6 105.8%  
Price / Book Value ratio x0.84.6 16.3%  
Dividend payout %010.7 0.0%   
Avg Mkt Cap Rs m5,8331,696,877 0.3%   
No. of employees `000NA17.5 0.0%   
Total wages/salary Rs m2,17949,023 4.4%   
Avg. sales/employee Rs ThNM18,028.3-  
Avg. wages/employee Rs ThNM2,798.8-  
Avg. net profit/employee Rs ThNM4,479.5-  
INCOME DATA
Net Sales Rs m10,089315,784 3.2%  
Other income Rs m2576,232 4.1%   
Total revenues Rs m10,346322,016 3.2%   
Gross profit Rs m-792100,893 -0.8%  
Depreciation Rs m36112,648 2.9%   
Interest Rs m2,7563,998 68.9%   
Profit before tax Rs m-3,65390,479 -4.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m099 0.0%   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m12512,116 1.0%   
Profit after tax Rs m-6578,462 -0.1%  
Gross profit margin %-7.831.9 -24.6%  
Effective tax rate %-3.413.4 -25.6%   
Net profit margin %-0.624.8 -2.6%  
BALANCE SHEET DATA
Current assets Rs m9,240329,537 2.8%   
Current liabilities Rs m9,998178,870 5.6%   
Net working cap to sales %-7.547.7 -15.7%  
Current ratio x0.91.8 50.2%  
Inventory Days Days4679 58.6%  
Debtors Days Days6083 72.0%  
Net fixed assets Rs m10,124204,766 4.9%   
Share capital Rs m2062,399 8.6%   
"Free" reserves Rs m5,582363,997 1.5%   
Net worth Rs m7,734366,397 2.1%   
Long term debt Rs m4,88914,361 34.0%   
Total assets Rs m22,882614,102 3.7%  
Interest coverage x-0.323.6 -1.4%   
Debt to equity ratio x0.60 1,612.9%  
Sales to assets ratio x0.40.5 85.7%   
Return on assets %11.813.4 87.6%  
Return on equity %-0.821.4 -3.9%  
Return on capital %22.324.8 89.8%  
Exports to sales %3.00-   
Imports to sales %0.40-   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m43NA-   
Fx inflow Rs m30744,118 0.7%   
Fx outflow Rs m12524,484 0.5%   
Net fx Rs m18119,634 0.9%   
CASH FLOW
From Operations Rs m11,75470,822 16.6%  
From Investments Rs m-561-42,216 1.3%  
From Financial Activity Rs m-6,762-22,854 29.6%  
Net Cashflow Rs m4,4326,107 72.6%  

Share Holding

Indian Promoters % 39.6 63.7 62.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 5.1 146.2%  
FIIs % 16.8 23.0 73.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 8.3 434.9%  
Shareholders   16,479 133,026 12.4%  
Pledged promoter(s) holding % 77.6 0.5 14,634.0%  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   AUROBINDO PHARMA  MERCK LTD  NOVARTIS  J.B.CHEMICALS  DR. REDDYS LAB  

Compare ELDER PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Firm US Markets; Sun Pharma, Software Stocks & Other Top Cues to Sway the Markets Today(Pre-Open)

Indian share markets finished the previous trading session on a strong note amid firm Asian markets after comments from a Federal Reserve official eased worries about faster rate hikes in US.

Related Views on News

Sun Pharma: Tough US Scenario Continues to Hit Business (Quarterly Results Update - Detailed)

Nov 20, 2017

The company's India business recovers but the pricing pressure and USFDA issues continue to mar the US revenues.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Sun Pharma: Price Erosion in US Impacts Growth (Quarterly Results Update - Detailed)

May 30, 2017

US markets decline while other geographies grow in the quarter.

Sun Pharma: Slow Growth Across Major Markets (Quarterly Results Update - Detailed)

Mar 11, 2017

Sun Pharma has announced its December quarter (3QFY17) results. The company has reported 8% YoY growth in sales and a decline of 4.7% YoY in the net profits.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

A New Quest for the Stock Market's MOST Profitable Ideas...(Smart Contrarian)

Feb 23, 2018

If you want to receive the best ideas in the Indian stick markets...you need to heed this important announcement.

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 5-YR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS